NAD+: The Complete Guide

NAD+: The Complete Guide

For research and educational purposes only. Nothing in this guide constitutes medical advice. Consult a qualified healthcare professional before beginning any new protocol. NAD+ is discussed here as a research compound and is not approved by Health Canada or the FDA for the research applications described in this guide.

Last updated: July 2026

---

NAD+ IV therapy is available at thousands of wellness clinics worldwide, and it’s been marketed with some of the boldest claims in this entire guide series — anti-aging, addiction recovery, long-COVID relief, hangover cures. Here’s the finding that should reframe how you read all of that: a rigorous, recent systematic review of the human literature found zero completed outcomes trials for injectable NAD+ itself, for any of those claims. This guide covers what’s actually been shown, what hasn’t, and how to think clearly about a compound with an unusually wide gap between its popularity and its evidence.

Quick Facts

Class	Coenzyme (not a peptide)
Primary research use	Cellular energy metabolism, DNA repair, longevity-oriented protocols
Administration	Subcutaneous or intravenous
First clinical use described	1961, for addiction treatment
Typical effective range (community-reported)	50mg–100mg per injection
Evidence tier	Real biological plausibility and tolerability data; zero completed outcomes trials for injectable use, per a 2025 systematic review
Regulatory status	Not approved anywhere for wellness or anti-aging use; named in Health Canada’s April 2026 advisory

The Story So Far

NAD+ has one of the more unusual histories in this guide series, because its clinical use as an injectable therapy is genuinely old — far older than almost any other compound covered here. It was first described in the clinical literature in 1961, by O’Hollaren, for the treatment of addiction. That’s over six decades of some clinical use predating the current wellness-clinic boom by a wide margin, though it’s worth being clear that early use for one specific, narrow purpose doesn’t constitute broad modern validation.

The current explosion of interest is much more recent and much broader in scope. NAD+ IV infusions are now available at thousands of boutique medical and hydration clinics globally, marketed for an unusually wide range of purposes: anti-aging and longevity, depression and anxiety reduction, drug and alcohol addiction support, hangover relief, fatigue, neurological conditions, athletic performance, and — more recently — recovery from long-COVID symptoms. That’s a genuinely broad set of claims for a single compound, and the breadth itself is worth noting as a pattern.

Academic interest in the underlying biology has grown substantially and is genuinely serious: a landmark 2025 review published in Nature Aging, co-authored by more than 25 scientists including Harvard’s David Sinclair and the University of Oslo’s Evandro Fei Fang, identified NAD+ as a key molecule of interest for aging and neurodegenerative disease research. That’s real, credible scientific attention — but it’s attention directed at the broader NAD+ biological pathway and its role in aging science generally, not a specific validation of injectable NAD+ therapy as currently marketed in wellness clinics.

On the regulatory side, NAD+ was specifically named in Health Canada’s April 2026 advisory on unauthorized injectable peptides — grouped alongside compounds like BPC-157 and CJC-1295 despite not being a peptide itself, reflecting the advisory’s broader concern with unauthorized injectable products generally rather than a peptide-specific classification.

What It Actually Does

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme — not a peptide, and not a hormone — that every cell in the body depends on for basic function. It acts as an electron carrier in the biochemical reactions that produce ATP, the cell’s energy currency, and it’s a required substrate for two other important processes: sirtuins, a family of enzymes involved in DNA repair and cellular stress response, and PARP enzymes, which directly repair damaged DNA. NAD+ levels decline meaningfully with age — commonly cited estimates suggest a decline in the range of 40 to 50 percent between young adulthood and middle age — and that decline is associated with reduced energy production, slower DNA repair, and several of the broader metabolic changes associated with aging. The core rationale behind NAD+ supplementation, in any form, is restoring something that naturally depletes over time.

What the Research Shows

This is the section where precision matters more for NAD+ than for almost any other compound in this guide series, because the gap between what’s marketed and what’s been shown is unusually wide.

Oral NAD+ precursors — nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — have real, if mixed, human clinical trial data. These compounds reliably raise NAD+-related biomarkers in the blood, confirming they do what they’re supposed to do at a biochemical level. Beyond that biomarker confirmation, though, outcomes that people actually care about — energy, metabolic health, vascular health, physical performance — show mixed, often endpoint-specific results across studies. A 2023 trial in postmenopausal women found improvements in muscle insulin sensitivity with NMN specifically, and some trials have found modest blood pressure reductions or reduced fatigue in older adults. This is genuine, if moderate, human evidence — better than what exists for injectable NAD+ itself.

Injectable NAD+ — the subcutaneous and IV administration this guide actually covers — has essentially no outcomes trial data at all. A rigorous, PRISMA-guided systematic review published in Ageing Research Reviews, examining human and animal intervention studies from January 2010 through October 2025, found no eligible outcomes trials evaluating IV or IM NAD+ itself for any anti-aging or wellness indication. This is a genuinely important, precise finding: despite widespread availability and enormous commercial popularity, the specific claim that injectable NAD+ improves aging-related or wellness outcomes in humans has not been tested in a completed, eligible trial as of that review’s cutoff.

What does exist for injectable NAD+ specifically is tolerability and pharmacokinetic data — smaller studies confirming it raises blood NAD+ levels and describing its side effect profile, including a retrospective real-world comparison of NAD+ IV against NR IV (both administered at 500mg over four consecutive days) that focused on tolerability and safety markers rather than efficacy outcomes. An active clinical trial (NCT06919328), comparing the absorption and tolerability of injectable NAD+ against an injectable NR formulation, was underway through mid-2025 — useful, ongoing research, but again focused on tolerability and absorption rather than the aging or wellness outcomes injectable NAD+ is actually marketed for.

There’s also a more technical scientific nuance worth understanding, since it complicates a common marketing claim: NAD+ itself may not be able to enter cells directly regardless of administration route. Because of its size and charge, NAD+ generally needs to break down into smaller pyridine-nucleotide components before it can cross into cells and be resynthesized — a metabolic step that applies whether it’s given orally, subcutaneously, or intravenously. This means the common marketing claim that injectable NAD+ “bypasses” the conversion process that oral precursors require is more complicated than it’s often presented — some researchers studying this specifically have also raised the theoretical possibility that artificially raising extracellular NAD+ levels could have effects beyond the intended ones, though this remains an area of active investigation rather than a settled concern.

How It Compares

NAD+ sits alongside MOTS-C in the longevity and cellular health category. (A full MOTS-C guide is part of this series.) The two work through genuinely different mechanisms and aren’t really substitutes for one another:

	NAD+	MOTS-C
Type	Coenzyme	Mitochondrial-derived peptide
Mechanism	Electron carrier for ATP production; substrate for sirtuins and PARP DNA-repair enzymes	AMPK activation — cellular energy sensing, glucose uptake, fat oxidation
Human outcomes trial data (injectable)	None found in a 2025 systematic review	Correlational human data; no injectable intervention trials
Typical use pattern	Ongoing, less cyclical	Cycled — 8–12 weeks on, 4–8 weeks off
Distinctive trait	Six-decade-old clinical use history, for an unrelated original indication	Discovered 2015; genuinely novel research category

Both compounds share the same basic rationale — restoring something the body produces less of as it ages — and both currently rest more on biological plausibility and correlational human data than on completed injectable-intervention outcomes trials. Neither should be understood as more clinically validated than the other for their respective wellness claims; the honest picture is that both are earlier in their evidence development than their popularity might suggest.

Who Shouldn’t Use This

NAD+ has no approved label for the wellness or longevity uses discussed here, so there’s no official contraindications list. Based on the available literature:

• History of low blood pressure or hypotension. NAD+ administration is associated with transient vasodilation — a real, physiologically expected effect — and this may be more pronounced in individuals prone to low blood pressure.
• Known cardiovascular conditions. Anyone with existing heart or vascular conditions should seek medical guidance before use, given the vasodilation effect.
• Pregnancy or breastfeeding. No human safety data exists in this context.

Beyond these, no established absolute contraindications exist in the published literature — reflecting the overall thinness of outcomes-focused human data for this route, not a confirmed absence of risk.

Common Myths, Addressed

“IV NAD+ has been clinically proven for anti-aging and wellness.” Not accurately, as of the most recent systematic review of the literature. Biological plausibility is strong, and biomarker changes are real, but completed outcomes trials for injectable NAD+ specifically, for these claims, don’t currently exist.

“Injectable NAD+ is a cleaner, more direct way to raise cellular NAD+ than oral precursors.” More complicated than that framing suggests. NAD+ generally needs to be broken down into smaller components before cellular entry regardless of route, which means the simple “injection bypasses the conversion step” claim doesn’t fully hold up mechanistically.

“Since it’s used in thousands of clinics, it must be well-studied.” Commercial availability and clinical study are two different things. A 2025 systematic review found zero eligible outcomes trials for injectable NAD+ specifically, despite its widespread clinical availability — popularity and evidence aren’t the same signal.

What Researchers Are Actually Experiencing

The flush — a wave of warmth, flushing, or tingling across the face, chest, and limbs in the minutes following administration — is the most commonly discussed immediate effect, and it’s genuinely one of the more distinctive experiences among the compounds in this guide series. It’s understood as a known effect of niacin-related compounds acting on receptors in skin and vasculature, and it’s generally considered more predictable and mechanistically understood than the flush phenomenon sometimes discussed with GH-axis compounds elsewhere in this series.

Slower administration and lower starting doses are consistently reported as the most effective way to manage flush intensity, and most researchers report it diminishing considerably after the first several sessions. Nausea is occasionally reported, again most commonly at higher doses or faster administration rates.

Community discussion around frequency is notably varied — daily, several-times-weekly, and once-weekly protocols are all commonly reported, without a strong consensus on which is superior, likely reflecting the same underlying evidence gap discussed above: without outcomes trials to anchor a standard protocol, community practice has diversified rather than converged.

This section reflects patterns commonly discussed across community research spaces. It’s observational rather than clinical trial data, and individual experience varies.

The Practical Basics

Research Ranges

Protocol	Research Range	Frequency
Assessment / starting	20–50mg	Once, to assess flush tolerance before increasing
Standard maintenance	50–100mg	Daily, 2–3x weekly, or weekly — highly variable in community practice
Upper community range	100–200mg	Per individual preference

Start at the lower end specifically to gauge your individual flush response before increasing — this is more relevant for NAD+ than for most compounds in this guide series, given how immediate and noticeable the flush can be.

Worked Dose Math

NAD+ vials are significantly larger than standard research peptide vials. At 100mg/mL (a 500mg vial reconstituted with 5mL BAC water):

• 50mg → 0.5mL → 50 units
• 100mg → 1mL → 100 units (a full standard syringe)

The underlying rule: volume (mL) = dose (mg) ÷ concentration (mg/mL), then ×100 for units on a U-100 syringe.

Vial Planning

A 500mg vial at 100mg/mL gives you 500mg total. At 50mg per session, three times weekly (150mg/week), that’s just over 3 weeks per vial.

Reconstitution and Storage — The Short Version

NAD+ reconstitutes with standard BAC water and should be used within 28 days once reconstituted, consistent with the general approach across this guide series. One genuine deviation worth knowing: NAD+ is more light-sensitive than most compounds covered here, both before and after reconstitution — keep it protected from light at all times, not just during storage. For the complete general process, see our dedicated reconstitution and storage guide.

Sourcing

Nothing NAD+-specific beyond the general picture — see our full guide on reading a Certificate of Analysis and vetting a vendor.

Administration

Subcutaneous injection is the most practical and accessible route for independent research use; intravenous administration produces a more pronounced, more rapid effect but requires IV access and is generally associated with supervised clinical settings. Administer slowly — over one to two minutes rather than as a rapid injection — to manage flush intensity. No fasting requirement. Timing is flexible; some researchers avoid bedtime administration given the flush’s potential to disrupt sleep onset.

Best Practices

• Start low and administer slowly — both meaningfully reduce flush intensity, more so than with almost any other variable.
• Protect from light more deliberately than with most other compounds in this guide series.
• Don’t assume more frequent dosing is inherently better — given the lack of outcomes trials to anchor a standard, this is genuinely an area where personal experimentation, done carefully, is doing more work than established protocol.
• Track your protocol from day one — dose, frequency, flush intensity, and any other observed effects.

Common Mistakes to Avoid

• Administering too quickly, which meaningfully worsens flush intensity and nausea risk.
• Assuming injectable use is better-evidenced than oral precursors — the comparison actually runs the other way for outcomes data specifically.
• Treating commercial popularity as a proxy for clinical validation — the systematic review finding is a direct correction to this assumption.
• Storing without adequate light protection, given this compound’s specific sensitivity.

What Happens If You Stop

There’s no dedicated discontinuation research for injectable NAD+. Given that it’s understood as restoring levels of something the body produces less of with age, rather than correcting a temporary or self-sustaining change, the reasonable expectation — consistent with how it’s discussed for oral precursors — is that any benefit would fade gradually as levels return toward baseline after stopping. This is a reasonable inference from the compound’s own framing, not a documented finding specific to the injectable route.

What to Expect, Week by Week

• First few sessions: The flush is typically most noticeable early on and is the dominant immediate experience; most researchers report it diminishing with repeated administration.
• Weeks 2–4: Community reports of fatigue or energy-related changes, where noted, tend to appear in this window, though — consistent with the evidence gap discussed throughout this guide — these reports aren’t cross-checkable against a completed outcomes trial.
• Ongoing: Many researchers treat this as a longer-term maintenance addition rather than a compound with a defined endpoint, similar in framing to GHK-Cu elsewhere in this series.

Individual timelines vary substantially, and this pattern comes entirely from community report rather than trial data for the injectable route specifically.

Combining With Other Compounds

NAD+ is commonly discussed alongside GLP-1 compounds and GH secretagogues in broader metabolic and longevity-focused protocols, on the general rationale that its cellular energy and DNA-repair mechanisms are complementary to — rather than overlapping with — appetite regulation or GH-axis stimulation. As with any multi-category combination discussed in this guide series, this rationale is based on the mechanisms not conflicting, not on a specific trial demonstrating a combined benefit.

Common Questions

Has NAD+ actually been proven to slow aging? Not in a completed human outcomes trial for the injectable form, as of the most recent systematic review. The underlying biology (NAD+ decline with age, its role in DNA repair and energy metabolism) is well-established; the specific claim that supplementing it reverses or slows human aging outcomes hasn’t been demonstrated in injectable form.

Is IV NAD+ better than subcutaneous injection? IV produces a faster, more pronounced effect and a more intense flush, but it requires clinical access and supervision. Neither route currently has completed outcomes trials supporting the wellness claims both are marketed for.

Should I use NAD+ or an oral precursor like NMN instead? They’re genuinely different evidence pictures — oral precursors have moderate human outcomes data with mixed results; injectable NAD+ has essentially none, though it does raise blood NAD+ levels reliably. Which makes more sense depends on what you’re optimizing for and how you weigh that evidence gap.

Why does the flush happen, and is it dangerous? It’s a known effect of niacin-related compounds on receptors in skin and vasculature — a real, expected, and generally benign physiological response, not an allergic reaction, though it can be intense at higher doses or with rapid administration.

Before You Start

A quick checklist to run through before your first dose:

• [ ] Confirmed you don’t have a history of hypotension or a cardiovascular condition that warrants extra caution
• [ ] Planned to start at a low dose (20–50mg) to assess your individual flush response
• [ ] Planned for slow administration (1–2 minutes) rather than a rapid injection
• [ ] Arranged for light-protected storage, given this compound’s specific sensitivity
• [ ] Understand that injectable NAD+ currently has no completed outcomes trials behind its most common marketing claims

Want this as a printable checklist alongside our compound reference plate? Download both from the resources section.

Common Protocol at a Glance

Protocol	Dose	Frequency
Assessment / starting	20–50mg	Once, then reassess
Standard maintenance	50mg–100mg	Daily to weekly — highly variable
Upper community range	100–200mg	Per individual preference

Where to Go From Here

• The Longevity Compound Group — NAD+ and MOTS-C compared in full
• Our Canadian Regulatory Landscape Guide
• Our Reconstitution and Storage Guide
• Our Certificate of Analysis and Vendor Verification Guide

---

This guide reflects the evidence and community research patterns available as of publication and will be updated periodically as new research emerges. It is provided for research and educational purposes only, does not constitute medical advice, and is not a substitute for consultation with a qualified healthcare professional. Aethon Labs does not intend for any compound discussed here to be used for human consumption.

AETHON LABS — Tested. Documented. Delivered.